Your browser doesn't support javascript.
loading
Initial experience using middle meningeal artery embolisation for patients with recurrent and high-recurrence-risk chronic subdural haematoma.
Flood, R; Nunn, A C; Talbott, J; Cox, A; Minks, D; Wareham, J; Crossley, R; Malcolm, G; Patel, N K; Wigfield, C; Williams, A; Mortimer, A.
Afiliación
  • Flood R; Southmead Hospital, North Bristol NHS Trust, United Kingdom. Electronic address: Richard.flood@nbt.nhs.uk.
  • Nunn AC; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Talbott J; Blackpool Victoria Hospital, Blackpool Teaching Hospital NHS Foundation Trust, United Kingdom.
  • Cox A; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Minks D; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Wareham J; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Crossley R; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Malcolm G; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Patel NK; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Wigfield C; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Williams A; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
  • Mortimer A; Southmead Hospital, North Bristol NHS Trust, United Kingdom.
J Clin Neurosci ; 125: 126-131, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38788605
ABSTRACT
Recurrence rates following surgical management of chronic subdural haematoma (CSDH) range from 5 to 33 %. There is growing evidence which suggests middle meningeal artery embolisation (MMAe) may reduce recurrence rates when used as surgical adjunct or standalone treatment. In this study we described our experience of this new procedure in the our UK institution. Patients with recurrent CSDH or CSDH at high risk of recurrence were selected for MMAe on a case-by-case basis following MDT discussion. A departmental database was used to identify patients treated. 26 CSDH were embolised in 20 patients; 9 CSDH were de-novo and 17 were recurrent. 10/26 CSDH were treated with MMAe only. No procedural mortality, access site or thrombo-embolic complications occurred. One patient experienced symptomatic collection growth 12 h following MMAe and required surgical drainage. 15 (75 %) of patients were living at home at follow-up (mean 14 months). On imaging follow-up 15/18 showed CSDH volume reduction or resolution, 1/18 remained stable requiring no further treatment, 2/18 patients suffered recurrent CSDH requiring treatment. In both recurrent cases incomplete embolisation was noted on procedural imaging (posterior division of MMA not embolised). Persistent posterior MMA division filling was significantly associated with collection recurrence (p = 0.002). Our results suggest MMAe as a stand-alone or adjuvant therapy can be performed safely in a UK neuroscience setting and is associated with high rates of symptomatic CSDH size reduction or resolution in problematic CSDH that have either recurred or are prone to recurrence.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recurrencia / Hematoma Subdural Crónico / Embolización Terapéutica / Arterias Meníngeas Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Neurosci Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recurrencia / Hematoma Subdural Crónico / Embolización Terapéutica / Arterias Meníngeas Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Neurosci Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido